Other Stories

Full Video

Pfizer agrees to license generic versions of Paxlovid to low-income countries Updated: 2021-11-17 12:13:03 KST

Pfizer has signed a deal to allow licensing for generic versions of Paxlovid, their COVID-19 oral treatment, in 95 low to middle income countries.
The drug has shown promising results in clinical trials is seen as a potential game changer with hopes pinned on saving lives in lower income countries where more than half of the world's population live.
The drug is expected to cost around 700 U.S. dollars, that price tag will most likely be brought down in those regions.
Pfizer's move, however, has been met with criticism that some of the hardest-hit countries,.. like Russia, Turkey, and Brazil, are not included in the deal.
KOGL : Korea Open Government License
본 저작물 중 본문에 해당하는 뉴스 스크립트(텍스트)는 공공누리 제1유형-출처표시 조건에 따라 이용할 수 있습니다.